NASDAQ: PROFProfound Medical Corp Stock
$4.78+0.06 (+1.27%)
Updated Apr 17, 2025
PROF Price
$4.78
Fair Value Price
N/A
Market Cap
$117.88M
52 Week Low
$3.90
52 Week High
$11.42
P/E
-6.06x
P/B
2.77x
P/S
25.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.52M
Earnings
-$19.32M
Gross Margin
65.9%
Operating Margin
-260.47%
Profit Margin
-260.4%
Debt to Equity
0.16
Operating Cash Flow
-$16M
Beta
0.97
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PROF Overview
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PROF's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PROF
Ranked#60 of 102
Ranked#60 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important PROF news, forecast changes, insider trades & much more!
PROF News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PROF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PROF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PROF is good value based on its book value relative to its share price (2.77x), compared to the US Medical Devices industry average (3.8x)
P/B vs Industry Valuation
PROF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PROF due diligence checks available for Premium users.
Valuation
PROF fair value
Fair Value of PROF stock based on Discounted Cash Flow (DCF)
Price
$4.78
Fair Value
-$4.82
Undervalued by
199.24%
PROF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PROF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.06x
Industry
41.14x
Market
27.98x
PROF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
3.8x
PROF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PROF's financial health
Profit margin
Revenue
$2.6M
Net Income
-$6.7M
Profit Margin
-261.6%
PROF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PROF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.8M
Liabilities
$6.8M
Debt to equity
0.16
PROF's short-term assets ($48.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PROF's short-term assets ($48.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PROF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PROF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
$0.0
Financing
$24.8M
PROF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PROF vs Medical Device Stocks
Profound Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.